DTIL Precision BioSciences Inc.

9.93
-0.17  -2%
Previous Close 10.1
Open 10.16
Price To Book 3.23
Market Cap 504,318,058
Shares 50,787,317
Volume 722,753
Short Ratio
Av. Daily Volume 1,363,197
Stock charts supplied by TradingView

NewsSee all news

  1. Precision BioSciences Announces FDA Acceptance of IND for PBCAR269A, a BCMA Targeted Genome Edited Allogeneic CAR T Therapy Candidate for Multiple Myeloma

    -Phase 1 clinical trial of off-the-shelf (allogeneic) anti-BCMA CAR T therapy candidate for patients with relapsed/refractory multiple myeloma expected to begin dosing patients in 2020- -PBCAR269A has received Orphan

  2. Precision BioSciences to Present at the 38th Annual J.P. Morgan Healthcare Conference

    DURHAM, N.C., Jan. 06, 2020 (GLOBE NEWSWIRE) -- Precision BioSciences, Inc. (NASDAQ:DTIL), a genome editing company dedicated to improving life through the application of its pioneering, proprietary ARCUS® platform,

  3. Precision BioSciences Presents Updated Interim Clinical Data at the ASH Annual Meeting from Relapsed / Refractory NHL and B-ALL Patients Treated at Dose Levels 1 & 2 in the Ongoing Phase 1/2a Clinical Trial of PBCAR0191, a Novel CD19 Targeted Allogeneic CAR T Therapy Candidate

    -PBCAR0191 continues to be associated with no serious adverse events or dose limiting toxicities observed to date, and no cases of graft-versus-host disease- -Seven of nine treated patients (78%) had objective

  4. Precision BioSciences Welcomes Healthcare Industry Expert, Kevin J. Buehler, to its Board of Directors

    DURHAM, N.C., Nov. 13, 2019 (GLOBE NEWSWIRE) -- Precision BioSciences, Inc. (NASDAQ:DTIL), a genome editing company dedicated to improving life through the application of its pioneering, proprietary ARCUS® platform,

  5. Precision BioSciences Reports Third Quarter 2019 Financial Results and Highlights Ongoing Operational Progress Including Initial Data from PBCAR0191 Phase 1/2a Clinical Trial

    DURHAM, N.C., Nov. 12, 2019 (GLOBE NEWSWIRE) -- Precision BioSciences, Inc. (NASDAQ:DTIL) ("Precision"), a genome editing company dedicated to improving life through the application of its pioneering, proprietary

Drug Information

Drug catalyst information is displayed when you hover over / tap on the stage bar graph.

Phase 1/2 updated data due 2020.
PBCAR0191
Relapsed or refractory B-cell precursor acute lymphoblastic leukemia and R/R non-hodgkin lymphoma
Phase 1/2 trial to be initiated 4Q 2019 with initial data due in 2020.
PBCAR20A
Chronic lymphocytic leukemia (CLL) and small lymphocytic lymphoma (SLL)
Phase 1 trial to commence in 2020.
PBCAR269A
Multiple myeloma

Latest News

  1. Precision BioSciences Announces FDA Acceptance of IND for PBCAR269A, a BCMA Targeted Genome Edited Allogeneic CAR T Therapy Candidate for Multiple Myeloma

    -Phase 1 clinical trial of off-the-shelf (allogeneic) anti-BCMA CAR T therapy candidate for patients with relapsed/refractory multiple myeloma expected to begin dosing patients in 2020- -PBCAR269A has received Orphan

  2. Precision BioSciences to Present at the 38th Annual J.P. Morgan Healthcare Conference

    DURHAM, N.C., Jan. 06, 2020 (GLOBE NEWSWIRE) -- Precision BioSciences, Inc. (NASDAQ:DTIL), a genome editing company dedicated to improving life through the application of its pioneering, proprietary ARCUS® platform,

  3. Precision BioSciences Presents Updated Interim Clinical Data at the ASH Annual Meeting from Relapsed / Refractory NHL and B-ALL Patients Treated at Dose Levels 1 & 2 in the Ongoing Phase 1/2a Clinical Trial of PBCAR0191, a Novel CD19 Targeted Allogeneic CAR T Therapy Candidate

    -PBCAR0191 continues to be associated with no serious adverse events or dose limiting toxicities observed to date, and no cases of graft-versus-host disease- -Seven of nine treated patients (78%) had objective

  4. Precision BioSciences Welcomes Healthcare Industry Expert, Kevin J. Buehler, to its Board of Directors

    DURHAM, N.C., Nov. 13, 2019 (GLOBE NEWSWIRE) -- Precision BioSciences, Inc. (NASDAQ:DTIL), a genome editing company dedicated to improving life through the application of its pioneering, proprietary ARCUS® platform,

  5. Precision BioSciences Reports Third Quarter 2019 Financial Results and Highlights Ongoing Operational Progress Including Initial Data from PBCAR0191 Phase 1/2a Clinical Trial

    DURHAM, N.C., Nov. 12, 2019 (GLOBE NEWSWIRE) -- Precision BioSciences, Inc. (NASDAQ:DTIL) ("Precision"), a genome editing company dedicated to improving life through the application of its pioneering, proprietary

  6. Precision BioSciences Announces the Presentation of Initial Clinical Data Supporting the Safety and Clinical Activity of PBCAR0191, a Novel CD19 Targeted Allogeneic CAR T Therapy Candidate, at the American Society of Hematology Annual Meeting

    -Preliminary data from ongoing Phase 1/2a trial of PBCAR0191 for the treatment of relapsed/refractory non-Hodgkin lymphoma or relapsed/refractory B-cell precursor acute lymphoblastic leukemia- -Abstract summarizes early

  7. Precision BioSciences to Report Third Quarter 2019 Financial Results and Present at Upcoming Investor Conferences in November

    DURHAM, N.C., Oct. 30, 2019 (GLOBE NEWSWIRE) -- Precision BioSciences, Inc. (NASDAQ:DTIL), a genome editing company dedicated to improving life through the application of its pioneering, proprietary ARCUS® platform,

  8. Precision BioSciences Appoints Nicholas Riddle, MB, BChir, PhD, as Vice President, Financial Strategy and Investor Relations

    DURHAM, N.C., Sept. 30, 2019 (GLOBE NEWSWIRE) -- Precision BioSciences, Inc. (NASDAQ:DTIL) ("Precision"), a genome editing company dedicated to improving life through the application of its pioneering, proprietary

  9. Precision BioSciences to Present at Upcoming Industry and Investor Conferences

    DURHAM, N.C., Sept. 26, 2019 (GLOBE NEWSWIRE) -- Precision BioSciences, Inc. (NASDAQ:DTIL), a genome editing company dedicated to improving life through the application of its pioneering, proprietary ARCUS® platform,

  10. Precision BioSciences Appoints David Thomson, PhD, as Chief Operating Officer

    DURHAM, N.C., Sept. 23, 2019 (GLOBE NEWSWIRE) -- Precision BioSciences, Inc. (NASDAQ:DTIL), a genome editing company dedicated to improving life through the application of its pioneering, proprietary ARCUS® platform,

  11. Precision BioSciences Announces FDA Clearance of the IND for PBCAR20A, a CD20 Targeting Genome Edited Allogeneic CAR T Therapy

    Phase 1/2a Clinical Trial of Off-The-Shelf Anti-CD20 CAR T Therapy Candidate in Patients with NHL, CLL, and SLL Expected to Begin in Fourth Quarter 2019PBCAR20A has Received Orphan Drug Designation for Mantle Cell